Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

wo Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and prulifloxacin, the timing of clinical trials and anticipated results, and plans related to regulatory filings and presentations of clinical trial results. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval, the timing of regulatory submissions and the uncertainty regarding whether such submissions will be accepted or approved, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts

    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005



                              Optimer Ph
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains ... therapeutic imaging within a body lumen (open space). ... a low cost, single-use disposable illumination and camera module ... 18, 2013 and the patent approval was received on ... to customize the lighting and magnification of the endoscope ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
(Date:5/20/2015)... 20, 2015 This year has been ... lawns. US Patented Pearl’s Premium Ultra Low Maintenance ... the country that are coming out of record bad ... number of major global concerns related to water, health, ... – the alternative to the standard, water-wasting, chemical-treated standard ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... laser systems, such as those intended to defuse unexploded mines, ... measurement device developed at the National Institute of Standards and ... at a U.S. Air Force base last week, will be ... systems. Light focused from a 10 kW laser is more ...
... Ltd. (Amex: SVA ), a leading provider of ... conference call on Friday, May 15, 2009 at 9:00 a.m. ... the period ended March 31, 2009 and provide an update ... 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the ...
... Amex: PIP ) a biodefense company developing ... date change for its first quarter 2009 financial results. ... be released on Friday, May 15, 2009.PharmAthene management will ... quarter 2009 financial results. The call is scheduled ...
Cached Biology Technology:New nanotube coating enables novel laser power meter 2Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... will receive a $900,000 check from Donald S. ... Region III which includes Pennsylvania, Virginia, Maryland, ... for continued research and education in the ... and underused industrial or commercial properties. The money, ...
... plant-eating predators to fight a superweed spreading throughout Britain ... a world expert on Japanese knotweed at the University ... of Biology has been researching the invasive weed since ... Hollingsworth and Catherine Pashley. Research in the ...
... Latest Generation of Mobile Data Software, WALL, ... Board: BKYI), a leader in finger-based biometric,identification and ... public safety software and related services orders that,closed ... 2008. Approximately fifty percent,of third quarter orders were ...
Cached Biology News:'Plant-eating predator to fight superweed is not magic bullet' 2BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders 2BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders 3
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... pending) is a protein based inhibitor of ... the most common and troublesome RNases including ... SUPERaseIn can be used in any application ... is ideal for in vitro transcription and ...
... Ribonuclease Inhibitor is a potent ... such as RNase A. Like ... Ribonuclease Inhibitor is an acidic ... ~52 kDa. RNaseOUT inhibits RNase ...
...
Biology Products: